BACKGROUND: Through migration, diversity of chronic hepatitis B virus (HBV) infection has changed, affecting disease burden and control. We describe clinical and viral characteristics of chronic HBV in the United Kingdom. METHODS: A total of 698 individuals with chronic HBV infection were recruited from referral liver centers. Demographic, clinical, and laboratory data were collected. RESULTS: Sixty-one percent of patients were male, 80% were not born in the United Kingdom, and the largest ethnicity was East/Southeast Asian (36%). Twenty-two percent were hepatitis B e antigen (HBeAg) seropositive; 20.4% (59/289) had cirrhosis and 10 (1.7%) had hepatocellular carcinoma. Genotype D was most common (31%) followed by A, C, B, and E (20%, 20%, 19%, and 9%, respectively). Genotype was significantly associated with country of birth, length of time in the United Kingdom, HBeAg status, and precore and basal core promoter mutations. One-third were on treatment, with men independently more likely to be treated. Only 18% of those on treatment were on recommended first-line therapies, and 30% were on lamivudine monotherapy. Among treated individuals, 27% had antiviral drug resistance. Testing rates for human immunodeficiency virus, hepatitis C virus, and delta coinfections were low. CONCLUSIONS: We demonstrated diversity of chronic HBV infections in UK patients, suggesting that optimal management requires awareness of the variable patterns of chronic HBV in countries of origin. We also found less-than-optimal clinical management practices, possible gender-based treatment bias, and the need to improve testing for coinfections.
BACKGROUND: Through migration, diversity of chronic hepatitis B virus (HBV) infection has changed, affecting disease burden and control. We describe clinical and viral characteristics of chronic HBV in the United Kingdom. METHODS: A total of 698 individuals with chronic HBV infection were recruited from referral liver centers. Demographic, clinical, and laboratory data were collected. RESULTS: Sixty-one percent of patients were male, 80% were not born in the United Kingdom, and the largest ethnicity was East/Southeast Asian (36%). Twenty-two percent were hepatitis B e antigen (HBeAg) seropositive; 20.4% (59/289) had cirrhosis and 10 (1.7%) had hepatocellular carcinoma. Genotype D was most common (31%) followed by A, C, B, and E (20%, 20%, 19%, and 9%, respectively). Genotype was significantly associated with country of birth, length of time in the United Kingdom, HBeAg status, and precore and basal core promoter mutations. One-third were on treatment, with men independently more likely to be treated. Only 18% of those on treatment were on recommended first-line therapies, and 30% were on lamivudine monotherapy. Among treated individuals, 27% had antiviral drug resistance. Testing rates for human immunodeficiency virus, hepatitis C virus, and delta coinfections were low. CONCLUSIONS: We demonstrated diversity of chronic HBV infections in UK patients, suggesting that optimal management requires awareness of the variable patterns of chronic HBV in countries of origin. We also found less-than-optimal clinical management practices, possible gender-based treatment bias, and the need to improve testing for coinfections.
Authors: P Keel; G Edwards; J Flood; G Nixon; K Beebeejaun; J Shute; J Poh; A Millar; S Ijaz; J Parry; S Mandal; M Ramsay; G Amirthalingam Journal: Epidemiol Infect Date: 2016-02-02 Impact factor: 4.434
Authors: John A Owiti; Trisha Greenhalgh; Lorna Sweeney; Graham R Foster; Kamaldeep S Bhui Journal: BMC Public Health Date: 2015-02-15 Impact factor: 3.295
Authors: Patrick T F Kennedy; Samuel Litwin; Grace E Dolman; Antonio Bertoletti; William S Mason Journal: Viruses Date: 2017-04-29 Impact factor: 5.048
Authors: Iro Evlampidou; Matthew Hickman; Charles Irish; Nick Young; Isabel Oliver; Sophie Gillett; Alexandra Cochrane Journal: Br J Gen Pract Date: 2016-03-29 Impact factor: 5.386
Authors: M I Andersson; T G Maponga; S Ijaz; J Barnes; G B Theron; S A Meredith; W Preiser; R S Tedder Journal: Vaccine Date: 2013-08-21 Impact factor: 3.641
Authors: C Crossan; E A Tsochatzis; L Longworth; K Gurusamy; V Papastergiou; E Thalassinos; K Mantzoukis; M Rodriguez-Peralvarez; J O'Brien; A Noel-Storr; G V Papatheodoridis; B Davidson; A K Burroughs Journal: J Viral Hepat Date: 2015-10-07 Impact factor: 3.728